Amyris Inc (NASDAQ:AMRS) Unveils The Financial Highlights For Its First Half 2019

Amyris Inc (NASDAQ:AMRS) has today given highlights of how it has been performing over the first half of 2019. The market will close on Wednesday, and shortly after, the business guru will hold a conference call. It will take advantage of this conference call to undertake a review of its business and financial results.

The turn of events in business

Apart from this, the company says it has also filed its Form 10-K for the previous year. The next step will be to file its Form 10-Qs for this year, and it will be for both the first and second quarters. This should happen before the conference call to be held on Wednesday. An official working with the company says it is important for them to complete these delinquent SEC filings. This is a way for them to comply with the Nasdaq listing rules.

Amyris President, who is also the CEO, is happy with this year’s financial results. According to him, the company has witnessed an impressive first-half. He thanks the teams in the company for their dedication. These teams have delivered greater volumes, and this has worked well towards attending to the fast-rising demand. The company official says that it means quite much for them to exceed their set business expectations.

He opined, “Our $300 million cannabinoid development collaboration is also exceeding our expectations. We are now on track to be the first company to produce multiple cannabinoids at commercial scale that are fermentation derived in 2020.”

A focus into the future

In the upcoming conference call, the company intends to do several things. The first one would be to discuss all aspects of its financial results. Secondly, it will give updates on its business outlook this year. Thirdly, it will discuss the way forward in terms of its ability to achieve even better results in the future.

A lot of the shareholders have been looking forward to seeing the company issue out its customary release earings. A person well conversant with the matter, but who wanted his identity kept anonymous says the company won’t be doing any such thing.

Amyris is set to unveil its financial results for both the first and the second quarter of this year. It is going to do that through the Form 10-Qs filing.

By Steven Russell

Steve covers business and investing in emerging medical marijuana markets. Steve graduated from the university of New Orleans with a degree in Broadcast Journalism. Steve has published several articles in professional journals and magazines. His experience gives readers an inside look at the intersection of his specialties, business and medical marijuana.

Leave a Reply

Your email address will not be published. Required fields are marked *

Amyris Inc (NASDAQ:AMRS) Is On Track To Exceed The Revenue Guidance Of $150 Million In 2019: Pipette Punecane Sweetener Baby Care Receives Wide Acceptance Amyris Inc (NASDAQ:AMRS) Receives Notice From Nasdaq For Not Keeping Time

Pin It on Pinterest